Empagliflozin vs Pembrolizumab

Empagliflozin vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Empagliflozin and Pembrolizumab.

Mechanism of Action

Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Empagliflozin — 12.4 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Empagliflozin — C23H27ClO7.

Molecular Weight: Empagliflozin — 450.9100 g/mol.

Type: Empagliflozin — Small molecule; Pembrolizumab — Antibody.